Delisting riskEarnings are out
BioLineRx (ADR) (BLRX)
Builds oncology assets around APHEXDA royalties and GLIX1 clinical development.
$2.66
Pre-market−0.00 (−0.08%)
At close$2.66(−3.62%)
Something off on this page? Send us feedback.
Next report
Nov 23, 2026
estimated · in 81 days
EPS estimate
−$0.39
Revenue estimate
$357.5K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$6.00$1.39−$1.00−$0.22−$0.27−$0.58−$0.77Pending
Estimate−$4.20−$0.84−$0.35−$0.41−$0.39−$1.04−$0.15−$0.39
Surprise+242.9%+265.5%−185.7%+46.3%+29.9%+44.2%−413.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$11.7M$255.0K$304.0K$427.0K$194.0K$477.0K$294.0KPending
Estimate$7.7M$1.8M$776.7K$670.0K$514.0K$343.0K$500.0K$357.5K
Surprise+52.2%−86.0%−60.9%−36.3%−62.3%+39.1%−41.2%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.39 | — | — |
| Aug 2026 | −$0.15 | −$0.77 | −413.3% |
| May 2026 | −$1.04 | −$0.58 | +44.2% |
| Mar 2026 | −$0.39 | −$0.27 | +29.9% |
| Nov 2025 | −$0.41 | −$0.22 | +46.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 23, 2026 | −$0.39 | — | — | $357.5K | — | — | — |
| Aug 31, 2026 | −$0.15 | −$0.77 | −413.3% | $500.0K | $294.0K | −41.2% | +7.7% |
| May 27, 2026 | −$1.04 | −$0.58 | +44.2% | $343.0K | $477.0K | +39.1% | +6.5% |
| Mar 23, 2026 | −$0.39 | −$0.27 | +29.9% | $514.0K | $194.0K | −62.3% | +4.3% |
| Nov 24, 2025 | −$0.41 | −$0.22 | +46.3% | $670.0K | $427.0K | −36.3% | +1.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| May 27, 2025 | |||||||
| Mar 25, 2025 | |||||||
| Nov 25, 2024 | |||||||
| Aug 15, 2024 | |||||||
| May 28, 2024 | |||||||
| Mar 26, 2024 | |||||||
| Nov 20, 2023 | |||||||
| Aug 30, 2023 | |||||||
| May 24, 2023 | |||||||
| Mar 22, 2023 | |||||||
| Nov 15, 2022 | |||||||
| Aug 16, 2022 | |||||||
| May 11, 2022 | |||||||
| Mar 16, 2022 | |||||||
| Nov 18, 2021 | |||||||
| Aug 18, 2021 | |||||||
| May 26, 2021 | |||||||
| Feb 23, 2021 | |||||||
| Nov 23, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 20, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 11, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 14, 2019 | |||||||
| Mar 28, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 13, 2018 | |||||||
| May 22, 2018 | |||||||
| Mar 6, 2018 | |||||||
| Nov 21, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 25, 2017 | |||||||
| Mar 23, 2017 | |||||||
| Nov 22, 2016 | |||||||
| Aug 11, 2016 | |||||||
| May 17, 2016 | |||||||
| Mar 10, 2016 | |||||||
| Nov 16, 2015 | |||||||
| Aug 20, 2015 | |||||||